Summary
Global Markets Direct’s, ‘Orion Oyj - Product Pipeline Review - 2016’, provides an overview of the Orion Oyj’s pharmaceutical research and development focus.
The report provides comprehensive information on the therapeutics under development by Orion Oyj, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the pipeline therapeutic landscape of Orion Oyj
- The report provides overview of Orion Oyj including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses Orion Oyj’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features Orion Oyj’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects
Reasons to buy
- Evaluate Orion Oyj’s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Orion Oyj
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Orion Oyj’s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
'
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Orion Oyj Snapshot 6
Orion Oyj Overview 6
Key Information 6
Key Facts 6
Orion Oyj - Research and Development Overview 7
Key Therapeutic Areas 7
Orion Oyj - Pipeline Review 10
Pipeline Products by Stage of Development 10
Pipeline Products - Monotherapy 11
Pipeline Products - Combination Treatment Modalities 12
Pipeline Products - Out-Licensed Products 13
Out-Licensed Products/Combination Treatment Modalities 14
Orion Oyj - Pipeline Products Glance 15
Orion Oyj - Late Stage Pipeline Products 15
Pre-Registration Products/Combination Treatment Modalities 15
Phase III Products/Combination Treatment Modalities 16
Orion Oyj - Clinical Stage Pipeline Products 17
Phase II Products/Combination Treatment Modalities 17
Phase I Products/Combination Treatment Modalities 18
Orion Oyj - Early Stage Pipeline Products 19
Preclinical Products/Combination Treatment Modalities 19
Discovery Products/Combination Treatment Modalities 20
Orion Oyj - Drug Profiles 21
(budesonide + formoterol fumarate) 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
(fluticasone propionate + salmeterol xinafoate) 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
levosimendan 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
ODM-201 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
dexmedetomidine hydrochloride 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
ODM-109 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
ODM-204 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
ODM-104 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
ODM-108 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
ODM-203 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Drugs to Agonize GABA-B Receptor for Central Nervous System Disorders 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
ORM-10103 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
ORM-3819 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Small Molecules to Inhibit BET Bromodomain for Oncology 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Small Molecules for Pain 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Orion Oyj - Pipeline Analysis 40
Orion Oyj - Pipeline Products by Target 40
Orion Oyj - Pipeline Products by Route of Administration 42
Orion Oyj - Pipeline Products by Molecule Type 43
Orion Oyj - Pipeline Products by Mechanism of Action 44
Orion Oyj - Recent Pipeline Updates 45
Orion Oyj - Dormant Projects 51
Orion Oyj - Discontinued Pipeline Products 52
Discontinued Pipeline Product Profiles 52
deramciclane 52
nitecapone 52
ODM-102 52
ODM-106 52
ORM-10921 52
Orion Oyj - Company Statement 53
Orion Oyj - Locations And Subsidiaries 55
Head Office 55
Other Locations & Subsidiaries 55
Appendix 57
Methodology 57
Coverage 57
Secondary Research 57
Primary Research 57
Expert Panel Validation 57
Contact Us 57
Disclaimer 58
List of Tables
Orion Oyj, Key Information 6
Orion Oyj, Key Facts 6
Orion Oyj - Pipeline by Indication, 2016 8
Orion Oyj - Pipeline by Stage of Development, 2016 10
Orion Oyj - Monotherapy Products in Pipeline, 2016 11
Orion Oyj - Combination Treatment Modalities in Pipeline, 2016 12
Orion Oyj - Out-Licensed Products in Pipeline, 2016 13
Orion Oyj - Out-Licensed Products/ Combination Treatment Modalities, 2016 14
Orion Oyj - Pre-Registration, 2016 15
Orion Oyj - Phase III, 2016 16
Orion Oyj - Phase II, 2016 17
Orion Oyj - Phase I, 2016 18
Orion Oyj - Preclinical, 2016 19
Orion Oyj - Discovery, 2016 20
Orion Oyj - Pipeline by Target, 2016 40
Orion Oyj - Pipeline by Route of Administration, 2016 42
Orion Oyj - Pipeline by Molecule Type, 2016 43
Orion Oyj - Pipeline Products by Mechanism of Action, 2016 44
Orion Oyj - Recent Pipeline Updates, 2016 45
Orion Oyj - Dormant Developmental Projects,2016 51
Orion Oyj - Discontinued Pipeline Products, 2016 52
Orion Oyj, Subsidiaries 55
List of Figures
Orion Oyj - Pipeline by Top 10 Indication, 2016 8
Orion Oyj - Pipeline by Stage of Development, 2016 10
Orion Oyj - Monotherapy Products in Pipeline, 2016 11
Orion Oyj - Combination Treatment Modalities in Pipeline, 2016 12
Orion Oyj - Out-Licensed Products in Pipeline, 2016 13
Orion Oyj - Pipeline by Top 10 Target, 2016 40
Orion Oyj - Pipeline by Route of Administration, 2016 42
Orion Oyj - Pipeline by Molecule Type, 2016 43
Orion Oyj - Pipeline Products by Top 10 Mechanism of Action, 2016 44
